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Medical Treatment of Cystic 
Echinococcosis
Irina Magdalena Dumitru
Abstract
Medical treatment in cystic echinococcosis is limited; albendazole remains the 
gold treatment for patients with low hydatid cysts or those with inoperable echino-
coccosis. Due to uncommon side effects, administration may be continuous (cycles 
of 28 days with a break of 14 days between courses) as well as discontinuous over 
long periods of time. In recent years, there have been many concerns for the testing 
of various substances and drugs against Echinococcus granulosus, both in vitro and 
in vivo, on the animal model, but the results have not been satisfactory. New clinical 
trials are required, as well as the development of an effective vaccine to limit the 
spread of echinococcosis in endemic areas.
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1. Introduction
Treatment of uncomplicated cystic echinococcosis (CE) is complex and consists 
of medical treatment, surgical and puncture, aspiration, injection, and reaspira-
tion (PAIR), depending on the characteristics of the cyst. For some cases (CE4 
and CE5), a conservative “watch and wait” approach is preferred (Table 1) [1, 2], 
because hydatid cysts may spontaneously regress with calcification without chemo-
therapeutic intervention [3].
Medical treatment has a role in reducing the size of cysts and stopping their 
development and reducing infectivity and is the only therapeutic option in inoper-
able cases. The combination of medical treatment with surgery (preoperative and 
postoperative administration) or PAIR plays a role in preventing recurrences [4].
2. The current state of knowledge 
Mebendazole (MBZ) was the initial agent, but it has proven less effective than 
albendazole over time (10–15 mg/kg/day, maximum 800 mg orally in two doses) 
[5]. Because MBZ is insoluble in water and has a poor solubility and bioavailabil-
ity, the drug is poorly effective [5]. The recommended regimen is 40–50 mg/kg/
day, orally in three divided doses during meals, in long-term therapy (more than 
2 years), and the success rate is 14–49% of cases [1]. MBZ is more effective in small 
cysts <5 cm in size, and the therapeutic response was superior in pulmonary (83%) 
than in hepatic (18%) locations [6]. MBZ treatment is well tolerated in long term 
therapy; adverse events have been described in 5–40% of patients—gastrointestinal 
distress, hair loss, neutropenia, anaphylactic reactions, glomerulonephritis, vertigo, 
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headache, psychic conspicuousness, hematotoxic effects, and abnormal levels of 
serum transaminases [7]—and so MBZ treatment is not recommended in pregnant 
women during the first trimester of pregnancy because it is associated with con-
genital abnormalities of the fetus [8].
The standard regimen of albendazole (ABZ) is cycles of 28 days with a break of 
14 days between courses, but duration of treatment is different depending on many 
factors.
Velasco-Tirado et al. show that in a meta-analysis performed on 33 cystic echi-
nococcosis treatment-related studies, there are insufficient data to standardize the 
results, and the optimal duration of therapy has not yet been established [9].
A study conducted by Dumitru et al., in Constanta, Romania, on 320 patients 
diagnosed with hydatid cyst, during 5 years (2008–2013), showed that six thera-
peutic cures were necessary before the first healing signs appeared [10] in most of 
cases and the response to treatment depends on the location of the cyst, size, and 
type according to Gharbi classification and immune status.
Related to location, albendazole treatment’s efficiency is higher in the case of 
hepatic or pulmonary localization than in other localizations (7.428571 ± 1.886039 
cures) [11]. Dimension <7 cm (especially <5 cm) responds better to medical treat-
ment, and the number of therapeutic cures administered for the CE1 (6.739 ± 1.91 
cures) is significantly smaller than the number of cures administered for the 
CE3 (8.181 ± 2.39 cures) [11]. Long-term treatment with albendazole (more than 
6 months) was only used for multiple or inoperable CE [11].
In the same study, we concluded that patients with good immune status 
responded better to albendazole treatment than to patients with CD4 < 500 cells/
mm3; also, the presence of comorbidities such as diabetes and chronic hepatitis was 
a negative predictive factor [11].
An additional study, conducted by the same team on a group of HIV-infected patients 
diagnosed with CE, with low CD4 (<200 cells/mm3), demonstrated that continuous 
therapy with albendazole 800 mg/day, administered more than 6 months, was not effec-
tive, and CD4 count can be a predictive factor for response to medical treatment [12].
Preoperative treatment with albendazole begins 1–3 months (average 14 days) 
before surgery and/or PAIR and continues for 1–3 months posttreatment [1, 3].
Because absorption of albendazole in humans is very variable, it is considered 
that concomitant administration of fatty meal would increase the absorption [13].
In recent years, the occurrence of resistance to albendazole has been frequently 
discussed, which greatly limits the medical treatment of echinococcosis [14]. Recent 
study conducted by Mortezaei et al. has shown that genetic makeup and miRNA 
WHO classification Suggested practice
CE1 Albendazole alone if <5 cm
PAIR + albendazole if >5 cm
CE2 Surgery + albendazole
or
Non-PAIR PT + albendazole
CE3a Albendazole alone if <5 cm
PAIR + albendazole if >5 cm
CE3b Surgery + albendazole
Non-PAIR PT + albendazole
CE4 and CE5 Wait and watch
Table 1. 
Treatment modalities stratified by cyst stage [1].
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profile of helminths affect their response to albendazole sulfoxide (ABZ-SOX) 
and revealed significant differential expression of let-7 and miR-61 at different 
drug concentrations [14]. This may explain the poor response to ABZ-SOX in some 
patients and requires the emergence of more effective new therapies.
A large meta-analysis conducted on 711 patients from 5 countries shows that 
multivesicular, multi-septated, and transitional cysts responded poorly to benz-
imidazoles (BMZ) and were associated to a high rate of relapses and BMZ are 
effective only in small cysts (diameter < 6 cm) [4]. Other factors that influence the 
response to therapy with benzimidazoles are age, because young patients respond 
much better to treatment than older people, and on the other hand, cyst localization 
influences the response to treatment; bone cysts were less susceptible to BMZ than 
hepatic or pulmonary echinococcosis [11, 15].
Albendazole long therapy is well tolerated; therefore, many clinicians prefer 
continuous therapy more than discontinuous therapy.
Because ABZ is nowadays considered a relatively safe drug, continuous therapy 
is preferred over discontinuous treatment protocols. The reported side effects were 
more frequent hepatotoxicity, alopecia, and gastrointestinal disturbances and less 
common jaundice, severe headache, cough, jaundice, vertigo, and itching [16]. ABZ 
is embryotoxic and teratogenic in pregnant women [17].
Recent studies have shown that concomitant administration of ABZ with certain 
drugs has a synergistic effect. Adding metformin to classical treatment with ABZ 
(an antidiabetic drug) has increased the efficacy of ABZ in vitro and in vivo (mouse 
models) [18, 19]. ABZ-mefloquine combined treatment seems a promising combi-
nation, with results slightly superior to monotherapy with ABZ [20].
In recent years, researchers’ efforts have focused on new ABZ formulations that 
lead to better tissue and organ penetration, including liposomes, biodegradable 
microspheres, and polymer conjugates. In this manner the drug is released for 
prolonged periods of time, improving the therapeutic effect [21].
Praziquantel (PZQ ) is a less effective antiparasitic drug than albendazole in the 
treatment of CE but in combination with ABZ might be helpful than ABZ alone in 
disseminated and inoperable cases [22, 23]. PZQ 40 mg/kg once a week in combina-
tion with ABZ 800 mg/day has proven more effective than ABZ alone, both before 
surgical intervention or PAIR and in the treatment of inoperable cases [23, 24]. 
Also, a combined therapy with ABZ 10 mg/kg/day and PZQ 25 mg/kg/day is effec-
tive as a prophylactic, preoperative treatment [25].
Isolated studies have demonstrated the antiparasitic properties of some drugs 
in vivo or only in vitro, but all studies have concluded that there is no alternative 
drug to albendazole to treat echinococcosis and it needs more research to discover 
new drugs [26, 27].
• Ursodeoxycholic acid had some scolicidal effects and can be administered to 
patients with poor response to albendazole therapy, in combination [28].
• Lawsonia inermis and Achillea millefolium extracts are a potent protoscolici-
dal which may be used as a scolicidal agent during the surgery. Achillea mille-
folium extracts at the concentration of 3 mg/ml after 5 minutes of exposure 
killed all of the protoscolices, and Lawsonia inermis extracts at concentration 
of 3 mg/ml after 10 minutes of exposure killed also all the protoscolices [28].
• Sodium arsenite (NaAsO2) administered in combination with albendazole 
significantly increases sensitivity of Echinococcus granulosus protoscoleces to 
ABZ, and the maximum protoscolicidal effect was seen with the combination 
20 μM NaAsO2 + 80 μM ABZ [29].
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• Garlic chloroformic extract had high protoscolicidal effects in recent study 
conducted by Barzin et al. in 2019 and could substitute other agents. The 
study compared the effectiveness of garlic extract with sodium chloride and 
silver nitrate and demonstrated that the protoscolicidal effects of the garlic 
extract at 1 (P < 0.001) and 2 (P < 0.001 and P = 0.003) minutes of exposure 
were higher than those of sodium chloride and silver nitrate. At 5 minutes 
of exposure, there was no difference between the garlic extract and sodium 
chloride (P = 0.36) [30].
• Anti-theilerial drugs MMV689480 (buparvaquone) and MMV671636 (ELQ-
400) have demonstrated a cytotoxic effect [29]. Buparvaquone impaired 
parasite mitochondria, and with an IC50 of 2.87 μM and 0.02 μM, respectively, 
against in vitro cultured E. multilocularis metacestodes, buparvaquone can be 
an effective therapeutic choice [31].
• Myrtus communis methanolic extract and Tripleurospermum disciforme have 
proven a scolicidal effect [30]. They can be used during hydatid surgery and 
could prevent the secondary infection. The results indicated that the high-
est scolicidal effect (100%) of M. communis was obtained at 100 and 50 mg/
ml concentrations and LC50 in 10, 20, and 30 minutes were 11.64, 7.62, and 
6.47 mg/ml, respectively. Further studies are required for identification of the 
active ingredients in the extracts [32].
• Chitosan nanoparticles containing curcumin (Ch-Cu NPs) had a good activ-
ity against Echinococcus granulosus in study published by Napooni et al. and can 
be considered an anti-protoscolex agent [33].
• Mebendazole C1 (M-C1) and mebendazole C2 (M-C2), two isoforms 
obtained from the reaction of mebendazole with epichlorohydrin, have 
superior efficacy on Echinococcus multilocularis protoscoleces and metaces-
todes compared to mebendazole [34]. It was also found that the introduction 
of an epoxy group to mebendazole reduced its cytotoxicity in rat hepatoma 
(RH) cells. The conclusion of the study was that introduction of an epoxy 
group to mebendazole improved the solubility of mebendazole, increased 
the parasiticidal effects on E. multilocularis, and reduced its cytotoxicity in 
RH cells [34].
• Anacardic acid (AA) is a natural product isolated from the Brazilian 
cashew-nut shell liquid and presented a high activity against metacestodes 
of Echinococcus multilocularis (E. multilocularis) and Echinococcus  
granulosus sensu stricto (E. granulosus s.s.) in vitro and in vivo [35]. Yuan  
et al. demonstrated that anacardic acid (AA) has better efficacy than alben-
dazole (ABZ) in vitro against Echinococcus metacestode and has similar 
efficacy to albendazole in vivo and the researchers concluded that AA may 
be an effective anti-Echinococcus drug in the future [36].
• Pentamidine (MMV000062), alpha-difluoromethylornithine 
(MMV001625), and suramin (MMV637953) were all tested in vivo against E. 
granulosus, but did not show any effects [36, 37].
• Rifampicin (MMV688775) and miltefosine (MMV688990) were ineffective 
in vivo against E. granulosus [36, 38].
5Medical Treatment of Cystic Echinococcosis
DOI: http://dx.doi.org/10.5772/intechopen.88545
• Amphotericin B (MMV689000) which is an antifungal drug has demon-
strated a good activity against E. multilocularis metacestodes in vitro at 2.7 μM 
[39–41]. Reiter et al. concluded that in some cases, amphotericin B therapy 
may be a salvage treatment in patients with progressive human alveolar 
echinococcosis [39] but is considered a limited therapy and is administered to 
well-selected patients due to increased nephrotoxicity [40, 42].
• Nitazoxanide (MMV688991) has been studied by Stettler et al. who dem-
onstrated that it has a good activity against E. granulosus metacestodes and 
protoscoleces in vitro [43–46]. Nitazoxanide was also tested in vivo in mice and 
in human patients with cystic (CE) and alveolar (AE) echinococcosis, but no 
beneficial effects were observed compared to ABZ [43–46].
• Auranofin (MMV688978) is a thioredoxin-glutathione reductase inhibitor and 
has the property of killing E. granulosus protoscoleces and is also active against 
E. multilocularis metacestodes [47, 48]. The studies reported a good efficacy 
in vitro at 2.5 μM after 48 h [49, 50].
• Mefloquine (MMV000016) is an antiparasitic drug used in malaria, active on 
Plasmodium spp., which has proven to be effective against Echinococcus multilocu-
laris metacestodes in vitro and in vivo [51–54]. In a study conducted by Küster 
(2011), oral administration of mefloquine (25 mg/kg of body weight admin-
istered twice a week for a period of 8 weeks) was compared with albendazole 
(200 mg/kg/day) or mefloquine intraperitoneally compared with albendazole. 
The study was performed on mice infected with Echinococcus multilocularis and 
showed similar efficacy of mefloquine administered intraperitoneally, compared 
to oral albendazole [52]. Oral administration of mefloquine at higher doses and 
over a long period of time (200 mg/kg, 5 days per week, during 4 weeks followed 
by treatments of 100 mg/kg during the last 7 weeks) had superior efficacy [53].
• Pomegranate peel aqueous extract (PGE) in combination with albenda-
zole has anti-hydating and anti-inflammatory effects in vivo, in mice infected 
with Echinococcus granulosus [55]. The researchers consider that PGE has a 
significant additive anti-hydatid effect and is beneficial in the preventive treat-
ment of recurrences [55].
• Pelargonium roseum and Ferula gummosa are essential oils with scolicidal properties, 
without side effect [56]. Tabari et al. have shown that protoscoleces of E. granulosus 
have a high potential against their two main constituents, citronellol and β-pinene, 
and toxic effect on E. granulosus in intraoperative use in hydatid cyst patients.
• BMZ analogs like fenbendazole, flubendazole, oxfendazole, and tricla-
bendazole have been evaluated in the last years, in vitro and in vivo studies 
(animal models), but did not provide superior efficacy compared to mebenda-
zole or albendazole [57].
• Ivermectin is an antiparasitic drug which is used against nematodes and has 
scolicidal activity if injected directly into the cyst during laparoscopy in a rodent 
but has a poor activity if administered orally due to low cyst penetration [58].
• Cyclosporine A is an immunosuppressant drug and described scolicidal activ-
ity in vitro and can be used for pre- and posttreatment in surgery or aspiration 
techniques [59].
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• Imatinib and pyridinylimidazoles (anti-neoplastic drugs, kinase inhibitors) 
show therapeutic effects on the parasite, both in vitro and in vivo, on the 
animal model [60].
• Natural compounds like thymol, menthol, and plant extracts (Trachyspermum 
ammi L. fruit essential oil, Zataria multiflora and Origanum vulgare essential oils, 
Salvia officinalis, Mentha spp. essential oil, Rosmarinus officinalis essential  
oil, Allium sativum methanol or chloroform extract, Berberis vulgaris aqueous 
extract, Cnidium monnieri osthole, Corylus spp., Curcurbita spp. hydroalcoholic 
extracts, Curcuma longa ethanol extract, Mallotus philippinensis fruit methanol 
extract, Nigella sativa seed essential oil, Olea europaea leaves aqueous extract, 
Penicillium extracted chitosan, Penicillium aculeatum in silver particles, Pestalotiopsis 
spp. ethyl acetate extract, Pistacia atlantica fruit methanol extract, Punica granatum 
peel aqueous extract, Salvadora persica root ethanol extract, Sambucus ebulus fruit 
methanol extract, Satureja khuzestanica leaves hydroalcoholic extract, Trametes 
robiniophila Murr. aqueous extract, and Zingiber officinale ethanol extract) have 
protoscoleces effects in vitro or in vivo, in different administrations such as oral or 
intragastric administration [57].
Recent studies have also tried to make albendazole more effective through 
nanotechnology. Ullio Gamboa et al. have demonstrated that ABZ lipid nanocap-
sules (ABZ-LNCs) are more effective than ABZ in vivo, in Echinococcus granulosus 
infected mice, in oral administration [61]. These results suggest that ABZ-LNCs 
could be a promising drug in the treatment of cystic echinococcosis in patients who 
are poorly responsive or nonresponsive to classical therapy with albendazole.
3. Future directions
In the future, vaccination could prevent the spread of echinococcosis in endemic 
regions. Zhao et al. identified six dominant T-cell epitopes and five dominant B-cell 
epitopes in the EgA31 protein structure and six dominant T-cell epitopes and three 
dominant B-cell epitopes in EgG1Y162 which may represent a beginning for multi-
epitope vaccines against Echinococcus granulosus [62]. Miles et al. identified 9 novel 
proteins and 14 peptides to be further tested as potential cystic echinococcosis 
vaccine candidates [63]. Pilot field trial of the EG95 vaccine against ovine cystic 
echinococcosis conducted by Larrieu et al. in Argentina demonstrated a decrease in 
EC incidence and a good surveillance and control tool in the epidemiological chain 
of the parasite [64].
The development of recombinant bi-vaccines expressing EG95 Echinococcus 
granulosus antigen is a new orientation in the future. Goatpox (GPV) disease and 
cystic hydatidosis can be prevented by live-attenuated GPV AV41 vaccine; the GPV 
is an ideal vector for expressing the EG95 antigen [65]. The same group of research-
ers have developed another recombinant, bivalent vaccine using morbillivirus 
(SRMV) which expresses EG95 antigen [66], preventing both morbillivirus infec-
tion and Echinococcus granulosus infection.
Given that treatment in the CE is limited, new clinical trials are needed to find 
potential drugs and new strategies to limit transmission of infection.
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